NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Pinetree Therapeutics

Pinetree Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://pinetreetx.com/en/index.php

Last Round

Series B

Oct 28, 2025

Est. Valuation

$135M

Total Funding Raised

$87.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Pinetree Therapeutics is a biotechnology company developing transformative therapies through targeted protein degradation for oncology and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

targeted protein degradationTPDmultispecific antibodydrug discovery platformbiotech licensingprotein degraderoncology therapeuticsbispecific antibodypreclinical biotechdrug resistanceprotein engineeringnext-gen therapeuticspharma partneringAI-augmented drug discoverydrug discovery tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pinetree Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Pinetree Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Pinetree Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BOct 28, 2025
Series A ExtensionJul 30, 2024
Series AJun 7, 2022

Key People

Founding team and executive leadership

Ho-Juhn Song

CEO Founder

Founding Team

Pinetree Therapeutics Investors

Notable investors and investment history

Pinetree Therapeutics investors
InvestorRounds
InterVestSeries A
SV InvestmentSeries B
DSC InvestmentSeries B, Series A, Series A Extension
Smilegate InvestmentSeries B
STIC InvestmentsSeries A Extension
Korea Investment PartnersSeries B
S&S InvestmentSeries B, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors increased 49% MoM.

  • Oct 28, 2025

    $47M round led by Atinum Investment and DSC Investment.

Pinetree Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pinetree Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pinetree Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range41
Year Founded2019
Last FundingOct 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.